Thera-SAbDab

BEZLOTOXUMAB

> Structural Summary

Therapeutic	Bezlotoxumab
Target	Toxin A
Heavy Chain	EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS
Light Chain	EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK
100% seqID Fv Structure	4np4 [Fvs: HL, IM]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4np4 [Fvs: HL, IM]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	NFD
Recorded Developmental Technology	Medarex HuMAb Mouse
INN Year Proposed	2012
INN Year Recommended	2013
Companies Involved	Medarex, University of Massachusetts Medical School, Merck & Co, Merck Sharp & Dohme
Conditions Approved	Clostridium difficile
Conditions Active	na
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]